"According to the latest research study, the demand for Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets grow from $31.6 in 2023 and is estimated ...

The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Researchers determined a short duration of anticoagulation therapy could be beneficial in comparison to a longer course for primary treatment VTE.

The multibillion-dollar worldwide market for injectable antithrombotic drugs (including anticoagulants and antiplatelet agents) will continue to grow as minimally invasive surgical interventions ...

Nonvalvular atrial fibrillation (AF) patients who take non-vitamin K oral anticoagulants (NOACs) along with certain other medications are at increased risk for major bleeding, and antithrombotic ...

The trial, which was published in The Lancet in 2013, demonstrated a significant reduction in bleeding risk with an oral anticoagulant and clopidogrel only — or “double therapy” — when ...

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of ...

Anticoagulant dosing for the treatment of venous thromboembolic events has been historically extrapolated from clinical experiences in adults, and although the most experience has been with ...

- RnRMarketResearch.com adds new market research reports "Antithrombotic / Anticoagulant Drugs: Technologies and Global Markets" to its store. This report provides an overview of the global market ...

The increasing incidence and accompanying increase in morbidity and mortality from VTEs in children will result in a steady increase in the usage of anticoagulants in children. As newer and better ...